ArticleCureus2025
A Case of Rocuronium-Induced Anaphylaxis Managed With Sugammadex.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaphylaxis is a severe, life-threatening complication that can result in complete cardiovascular and respiratory collapse. Peri-operatively, this complication is most often seen after the intravenous (IV) induction of general anesthesia, and the most common responsible agents are non-depolarizing neuromuscular blocking agents. In this report, we describe a case of perioperative anaphylaxis induced by the non-depolarizing neuromuscular blocker rocuronium. Sugammadex, a reversal agent for the non-depolarizing muscle relaxants rocuronium and vecuronium, was administered shortly after induction. The patient showed rapid clinical improvement in blood pressure, heart rate, and oxygen saturation values within minutes of sugammadex administration. We suggest that sugammadex should be considered as an adjunct therapy when treating anaphylaxis caused by rocuronium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.